Sana Biotechnology Business Model Canvas

CDMOs and GMP suppliers give Sana capacity, redundancy, and specialized equipment for viral vectors, LNPs, and cell processing, with the global biologics CDMO market estimated at roughly $140 billion in 2024, underscoring available scale. Qualified raw materials and robust quality systems reduce batch-failure risk and support regulatory compliance. Tech-transfer partners enable parallel scale-up while internal plants mature, balancing speed, cost, and compliance.

Key partnerships accelerate discovery, trial execution, manufacturing scale-up and market access: universities/hospitals supply models and sites (>1,500 global CGT trials in 2024), CDMOs provide capacity (global biologics CDMO market ~$140B in 2024), licensors supply editors/delivery (gene‑editing market ~12% CAGR in 2024), payers/patient groups enable reimbursement (CAR-T list prices ~$373–475k).

Process development locks in reproducible GMP manufacturing for cells, vectors, and delivery vehicles, aligned with ICH and FDA GMP expectations. Comparability, release testing, and stability studies are validated early to support regulatory filings. Automation and closed systems lower contamination risk and operating variability. Structured tech-transfer protocols ensure reliable multi-site manufacturing scale-up.

Engineering in vivo delivery, ex vivo cell modification and gene-control platforms iteratively advance specificity and durability; platform active since 2018 (Sana). GLP pharmacology/toxicology and biomarker-driven early trials (20–120 pts) de-risk IND entry and guide dose/patient selection. GMP process development, global regulatory engagement (US, EU, UK, Japan) and alliance management enable scale and portfolio prioritization.

GMP-qualified suites with single-use systems and robust cold-chain logistics underpin product integrity from fill/finish to distribution. Redundant suppliers for media, plasmids and consumables minimize bottlenecks for critical materials. Integrated digital batch records and on-site QC labs drive reliable lot release and traceability. Dynamic capacity planning aligns suites and CMO partnerships to clinical and commercial demand.

In vivo delivery platforms, modular payload control and GMP biomanufacturing form Sana’s core resources, backed by patents, trade secrets and multidisciplinary scientific/clinical teams advancing IND-enabling programs in 2024. Sana held roughly $1.08 billion cash and investments at year-end 2024; integrated data and biobanks accelerate translation.

Off-the-shelf allogeneic cells offer faster access and materially lower per-dose economics versus individualized autologous manufacturing, supporting inventory-based supply and broader patient coverage. Standardized processes improve batch quality and logistics, enabling community-center adoption over time. Sana reported a pipeline of over 20 programs in 2024, underscoring scalability potential.

Engineered cells and in vivo gene delivery target root causes for durable, often one-time benefit; gene therapy market ~$13B in 2024 and precedent prices (Zolgensma ~$2.1M, Luxturna ~$850k) show lifetime cost offsets. Targeted delivery improves safety and widens eligibility; Sana (Nasdaq: SANA) reported >20 programs in 2024 across oncology, diabetes, neurology. Off-the-shelf allogeneic cells cut per-dose economics and enable inventory-based scale.

Patient support programs deploy navigation services to reduce access friction, cutting administrative delays and streamlining referrals; studies show tailored navigation can improve initiation and coordination. Financial assistance and travel support lower cost and logistical barriers, boosting treatment starts, while adherence and remote monitoring tools sustain outcomes with reported adherence uplifts around 20%. Clear, consistent communication fosters trust in novel modalities and improves persistence.

Co‑creation with KOLs and investigators aligns protocols to practice amid >430,000 trials on ClinicalTrials.gov (2024), aiding recruitment and credibility. Medical affairs provides non‑promotional HCP education and center certification while patient navigation and financial support raise initiation and adherence (real‑world uplifts ~20% in 2024).

Data dissemination at major meetings (eg ASH 2024 drew ~21,000 attendees) and in journals builds awareness and trust among HCPs and payers, supporting reimbursement narratives. Late-breaker presentations spotlight clinical inflections and valuation drivers. Peer-reviewed publications validate claims through independent scrutiny. Sustained thought leadership keeps investor and collaborator interest on Sana’s pipeline.

Direct hospital centers, partner co-commercial teams, scientific dissemination and digital portals form Sana’s multi-channel go-to-market, enabling rapid launches and scale; cell and gene therapy market >$10B (2024), global pharma ~$1.6T (2024). ASH attendance ~21,000 (2024) and cold-chain market ~USD 240B (2024) validate demand and logistics readiness.

Biopharma partners seek Sana’s delivery, editing and cell-engineering capabilities to accelerate pipelines via co-development or licensing, expanding target portfolios and therapeutic modalities; in 2024 the global cell and gene therapy market was estimated at about $7.2B, underscoring demand. They prioritize speed, de-risked CMC and clear IP to shorten timelines and avoid late-stage setbacks. Milestone-based payment structures align incentives, sharing upside while reducing upfront risk for both parties.

Patients: oncology 1.9M new US cases (2024), T1D ~1.6M US, AD/dementia ~6.7M US; high unmet need and willingness for novel cell/gene therapies. Clinicians: oncologists/endocrinologists/neurology; >200 US CAR‑T hospitals (2024). Biopharma: cell/gene market ≈$15B (2024). Payers/HTA: global medicine spend $1.5T (2023); NICE £20–30k/QALY. Academia: Sana cash ≈$1.1B (2024).

GMP operations, QC/QA and high-grade raw materials are major cost centers in Sana Biotechnologys CMC, driving both recurring COGS and compliance overheads.

Scale-up and validation campaigns remain capital intensive; in 2024 building a GMP gene therapy facility typically ranged from $200 million to $500 million in upfront capex.

Redundancy for risk mitigation and comparability studies add recurring expense, while incremental yield improvements materially enhance margins—single-digit yield gains can cut cost-per-dose significantly.

Major costs: R&D $424M in 2024, labs/equipment and specialized talent drive high fixed burn. Clinical development typically $300k–$1M per patient with trials 45–60% of spend; biomarker/imaging add $50k–$200k per patient. GMP capex $200M–$500M; launch commercialization $200M–$400M; FDA fee ~3.2M.

Royalties provide Sana an ongoing percentage of partner product sales tied to licensed IP, scaling directly with market penetration and patient uptake. In 2024 industry royalty structures for biologics commonly sit in single-digit to low-teen percentage ranges, giving long-dated tails that enhance cash-flow predictability. Multiple stacked royalties across indications increase headline rates but require optimization to avoid margin erosion and partner resistance.

As of 2024 Sana has no commercial products; near-term revenue comes from upfronts/milestones, royalties, manufacturing/tech-transfer fees, and data/diagnostics partnerships. Gene therapy prices range ~$0.85M–2.8M; vector manufacturing market ~$4.3B and companion diagnostics ~$6.7B in 2024. Royalties typically single-digit to low-teen percent; deals provide non-dilutive cash and recurring service income.